Amarin Corporation plc (AMRN)
AMRN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/0001193125-26-085818-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | AMRN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Ireland |
| IPO year | Not reported by the screener |
| SEC CIK | 0000897448 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | United Kingdom |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $213.6M |
| Net income | -$38.8M |
| Operating income | -$50.2M |
| Net margin | -18.2% |
| Operating margin | -23.5% |
| Revenue growth | -6.5% |
| Cash | $134.7M |
| Total assets | $670.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-28 |
| Cash and burn | $156.5M cash; operating cash flow $9.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 21,073,239 (2026-10-31); 20,792,684 a year earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | 1; latest 1-for-20 on 2025-04-11 | Source 2025-04-11 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Iselin, New Jersey, United States | PCAOB Form AP 2026-03-25 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $39.5M | $245K | $9.2M | $156.5M | No debt tags | $176.1M | 10-Q 2026-10-28 |
| Q2 2026 2026-06-30 | $42.2M | -$7.7M | $6.6M | $143.6M | No debt tags | $186.2M | 10-Q 2026-07-29 |
| Q1 2026 2026-03-31 | $45.1M | -$10.5M | $6.4M | $131.1M | No debt tags | $216.8M | 10-Q 2026-04-29 |
| Q4 2025 2025-12-31 | $49.2M | -$1.2M | $15.3M | $134.7M | No debt tags | $213.6M | 10-K 2026-03-02 |
| Q3 2025 2025-09-30 | $49.7M | -$7.7M | -$12.7M | $122.8M | No debt tags | $226.7M | 10-Q 2026-10-28 |
| Q2 2025 2025-06-30 | $72.7M | -$14.1M | $16.6M | $147.9M | No debt tags | $219.4M | 10-Q 2026-07-29 |
| Q1 2025 2025-03-31 | $42.0M | -$15.7M | -$12.5M | $119.5M | No debt tags | $214.1M | 10-Q 2026-04-29 |
| Q4 2024 2024-12-31 | $62.3M | -$48.6M | -$13.3M | $121.0M | No debt tags | $228.6M | 10-K 2026-03-02 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2023-08-02 |
| Latest annual report | 10-K | 2026-03-02 |
| Latest quarterly / interim | 10-Q | 2026-10-28 |
| Latest current report | 8-K | 2026-10-28 |
| Latest proxy | DEF 14A | 2026-04-10 |
Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.0% |
| 1 month | -1.7% |
| 3 months | -19.6% |
| Year to date | -18.5% |
| 1 year | -30.1% |
| From 52-week high | -33.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VNDA | Vanda Pharmaceuticals Inc. | $3.81 | -4.51% | $230.4M |
| IMRX | Immuneering Corporation | $3.52 | -5.12% | $228.0M |
| ARCT | Arcturus Therapeutics Holdings Inc. | $8.31 | -0.60% | $239.5M |
| FTH | Faeth Therapeutics Inc. | $9.28 | -7.48% | $239.8M |
| BIOA | BioAge Labs Inc. | $5.22 | -5.95% | $239.9M |
| RCKT | Rocket Pharmaceuticals Inc. | $2.16 | -6.09% | $241.2M |
| CAMP | CAMP4 Therapeutics Corporation | $3.86 | +1.58% | $242.2M |
| LFCR | Lifecore Biomedical Inc. | $6.42 | -0.08% | $243.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier